NASDAQ:CELC
Celcuity Inc Stock News
$17.67
+0.0100 (+0.0566%)
At Close: May 03, 2024
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
07:05am, Thursday, 04'th Apr 2024
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian
Why Celcuity (CELC) Might Surprise This Earnings Season
12:21pm, Thursday, 21'st Mar 2024
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
07:05am, Wednesday, 20'th Mar 2024
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
11:02am, Friday, 01'st Dec 2023
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abs
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
07:30am, Monday, 06'th Nov 2023
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
07:05am, Wednesday, 01'st Nov 2023
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
04:43pm, Thursday, 21'st Sep 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
7 Short-Squeeze Stocks That Actually Might Make Sense
07:10pm, Wednesday, 06'th Sep 2023
Some of the most speculative ideas are the targeted short-squeeze stocks. To better understand what's going on, it's helpful to think of a timed chess match.
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
07:30am, Thursday, 03'rd Aug 2023
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it w
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
08:00am, Wednesday, 24'th May 2023
MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian
Celcuity Inc. (CELC) Q1 2023 Earnings Call Transcript
10:47pm, Monday, 15'th May 2023
Celcuity Inc. (NASDAQ:CELC ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Conferen
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
05:30pm, Monday, 08'th May 2023
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication
Celcuity Inc. (CELC) Q4 2022 Earnings Call Transcript
08:04pm, Thursday, 23'rd Mar 2023
Celcuity Inc. (NASDAQ:CELC ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor G
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
08:00am, Thursday, 16'th Mar 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it w
